American Shared Hospital Services vs Biodesix
AMS and BDSX side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMS and BDSX compare
Biodesix is the larger company, worth 15 times as much as American Shared Hospital Services ($104M against $7.2M).
Biodesix grew revenue faster over the last twelve months (31.2% versus 4.9% for American Shared Hospital Services).
American Shared Hospital Services keeps more of each dollar of sales as profit, with a net margin of −7.7% compared with −25.7% at Biodesix.
American Shared Hospital Services scores higher on the StockData Score (6 against 4 for Biodesix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMS | BDSX |
|---|---|---|
| Size and price | ||
| Market cap | $7.2M | $104M |
| Share price | $1.08 | $9.88 |
| Change, 1 year | −48.1% | 24.3% |
| Change, 5 years | −59.4% | −92.3% |
| Beta (5Y) | 0.37 | 0.74 |
| Employees | 44 | 334 |
| StockData Score | ||
| Total score | 6 (better) | 4 |
| Valuation score | 4 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.2× (better) | 1.0× |
| P/B | 0.3× (better) | 12.0× |
| EV/EBITDA | 1.8× | – |
| P/FCF | 1.0× | – |
| FCF yield | 96.2% (better) | −18.3% |
| Fair value | $4.19 | – |
| Margin of safety | 74.2% | – |
| Growth | ||
| Revenue growth (TTM) | 4.9% | 31.2% (better) |
| Revenue growth, 5Y average | 9.5% | 14.2% (better) |
| Profitability | ||
| Gross margin | 16.7% | – |
| Operating margin | −13.0% (better) | −18.7% |
| Net margin | −7.7% (better) | −25.7% |
| FCF margin | 22.4% (better) | −18.1% |
| Return on equity | −10.1% (better) | −779% |
| Return on invested capital | −11.9% (better) | −55.4% |
| Financial health | ||
| Debt / equity | – | 5.43 |
| Interest coverage | −2.8× | −2.5× (better) |
| Current ratio | 0.81 | 2.96 (better) |
| Altman Z-score | 0.45 (better) | −6.24 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | −31.4% |
| Shareholder yield | 0.00% (better) | −31.4% |
| Ownership | ||
| Held by institutions | 7.6% | 41.4% |
| Held by insiders | 38.1% | – |
| Insider net buying, 12 months | $1.3M | $4.0M (better) |
| Short interest, % of float | 0.28% | – |
Go deeper
- AMS stock overview
- AMS income statement
- AMS valuation and score
- BDSX stock overview
- BDSX income statement
- BDSX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.